---
document_datetime: 2023-09-21 19:45:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_en.pdf
document_name: lartruvo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9031055
conversion_datetime: 2025-12-19 03:26:03.403386
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented)    | Strength   | Pharmaceutical Form                   | Route of                       | Immediate              | Content               | Pack size   |
|------------------|---------------|------------|---------------------------------------|--------------------------------|------------------------|-----------------------|-------------|
| EU/1/16/1143/001 | name Lartruvo | 10 mg/ml   | Concentrate for solution for infusion | Administration Intravenous use | Packaging vial (glass) | (concentration) 50 ml | 1 vial      |
| EU/1/16/1143/002 | Lartruvo      | 10 mg/ml   | Concentrate for solution for infusion | Intravenous use                | vial (glass)           | 19 ml (190mg/19ml)    | 1 vial      |
| EU/1/16/1143/003 | Lartruvo      | 10 mg/ml   | Concentrate for solution for infusion | Intravenous use                | vial (glass)           | 19 ml                 | 2 vials     |

<!-- image -->